Alerta

一种兽用复方黄芪多糖注射液及其生产工艺

Resumen de: CN119868272A

本发明公开了一种兽用复方黄芪多糖注射液及其生产工艺，属于兽用医药配制品技术领域，包括如下步骤：将黄芪多糖溶解后与复合纳米颗粒复合得到黄芪多糖负载粉末；将表面活性剂和无水乙醇加入液体石蜡中，将分散液边搅拌边加入反应釜中，然后搅拌得到复方黄芪多糖注射液；本发明的生产工艺通过将环糊精制备成载体吸附和封装黄芪多糖，并利用环糊精载体的吸附能力与聚乳酸形成核壳结构，将包覆有纳米硒的聚乳酸负载在环糊精载体内，既阻止了纳米硒在注射液中的团聚，也使黄芪多糖分散性提高，通过将复合纳米颗粒制备成乳液，提高复合纳米颗粒的分散性，乳液形态的注射液更容易被动物吸收，使纳米硒与黄芪多糖产生协同作用，提高动物的抵抗力。

具有抗菌功能的含铁脂质纳米粒IO-LNPs的制备方法和应用

Resumen de: CN119868304A

本发明属于纳米技术领域，具体公开了一种具有抗菌功能的含铁脂质纳米粒IO‑LNPs的制备方法和应用。以油酸铁、大豆卵磷脂和DSPE‑MPEG2000为原料，通过梯度溶剂扩散法合成了具有抗菌功能的含铁脂质纳米粒(IO‑LNPs)，其能诱导细菌铁死亡效应，具有良好的抗菌活性，能够有效杀灭革兰氏阳性(S.aureus，)和阴性(E.coli)菌株，而且对S.aureus和E.coli具有良好的生物膜预防和破坏能力。本发明制备的具有抗菌功能的含铁脂质纳米粒IO‑LNPs在生理条件下表现出较高的稳定性和生物相容性，在抗菌性能上具有优异的效果，是对抗细菌感染和促进伤口愈合的安全高效的药剂。

視力喪失を治療するためのｔＲＮＡ療法に関連する方法及び組成物

Resumen de: AU2023256601A1

Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.

NANOPARTICLES CAPABLE OF REALIZING CONTROLLED RELEASE OF CARBON MONOXIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025081381A1

Nanoparticles capable of realizing controlled release of carbon monoxide, and a preparation method therefor and the use thereof. The nanoparticles capable of realizing controlled release of carbon monoxide comprise triiron dodecarbonyl and Croc-PEG that coats triiron dodecarbonyl, wherein Croc-PEG is a condensation product of Croc and MPEG-NH2. The nanoparticles capable of realizing controlled release of carbon monoxide can effectively improve the loading capacity of carbon monoxide, thereby achieving controlled release of carbon monoxide and high-efficiency low-toxicity CO gas therapy.

IONIZABLE LIPID NANOPARTICLES FOR IN UTERO mRNA DELIVERY

Resumen de: US2025127720A1

Disclosed herein is a method for the delivery of prenatal therapeutics, enzyme replacement therapy, or gene therapy to a fetus in need thereof. The method comprises introducing ionizable lipid nanoparticles (LNPs) nanoparticles comprising a therapeutic mRNA composition into the circulation of the fetus in need of treatment such that the ionizable LNPs deliver the therapeutic mRNA composition.

TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA

Resumen de: AU2025202461A1

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAIl or DNAH5.

PSMA LIGAND TARGETED COMPOUNDS AND USES THEREOF

Resumen de: US2025127935A1

Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO

Resumen de: US2025127925A1

Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Telmisartan Nanosuspension for Therapy of Respiratory Infections and Methods of Making and Using Same

Resumen de: US2025127761A1

A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.

Self-Assembling Nanoparticles Based On Amphiphilic Peptides

Resumen de: US2025127887A1

The present disclosure relates to a vaccine comprising an amphiphile having the formula S-B-U-H and at least one peptide antigen conjugate having the formula selected from S-E1-A-E2-U-H and H-U-E1-A-E2-S, wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.

PH-RESPONSIVE NANO PARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS

Resumen de: US2025127921A1

Provided herein are self-assembled nanoparticles (NPs), pharmaceutical compositions containing such NPs and methods of using such NPs. The NPs comprise an amphiphilic copolymer and a ribonucleoprotein (RNP), and optionally ssODN, wherein: the amphiphilic copolymer is a water-soluble block copolymer comprising a poly(C2-3 alkylene glycol) block and an acrylic block comprising a poly(acrylate), poly(methacrylate) or poly(acrylate/methacrylate) block; the acrylic block comprise ester side chains bearing substituted or unsubstituted alkylamine groups; and the RNP, ssODN, and the acrylic block of the amphiphilic copolymer form a core of the self-assembled nanoparticle, and the poly(ethylene glycol) block of the amphiphilic copolymer forms the exterior of the self-assembled nanoparticle.

NUCLEIC ACID-LIPID NANOPARTICLE AND METHOD USING THE SAME

Resumen de: US2025127882A1

A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.

METHODS OF LOADING EXTRACELLULAR VESICLES

Resumen de: US2025127919A1

The present disclosure relates to methods of loading an EV with a payload. In some aspects, the payload and the EV are mixed at a specific loading condition (e.g., at the disclosed salt concentrations, loading temperature, loading duration, payload feed concentration, and/or EV feed concentration), such that the amount of the payload that is associated with the exterior surface of the EV is increased. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

HYPERACTIVATING LIPID NANOPARTICLES

Resumen de: US2025127868A1

The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

NANOPARTICLE VECTOR FOR RNA SELF-DELIVERY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: US2025129386A1

The present disclosure discloses a nanoparticle vector for RNA self-delivery and a preparation method therefor and use thereof. The nanoparticle vector includes: a β-cyclodextrin-RNA conjugate, an adamantane-ligand conjugate, and a cationic polymer, wherein the adamantane-ligand conjugate is formed by conjugating adamantane with a ligand molecule through polyethylene glycol. Through a host-guest interaction between β-cyclodextrin and an adamantane molecule, the nanoparticle vector can realize the modular conjugation of a delivered RNA molecule and the ligand molecule, and realize the self-delivery of RNA. The polyethylene glycol molecule can avoid the recognition and phagocytosis of immune cells before the vector enters target cells, and β-cyclodextrin can realize the escape of intracellular nucleosome. The nanoparticle vector delivers RNA to cells in a targeted manner, and is degraded in vivo via endocytosis, releasing RNA molecules to inhibit expression of genes of interest, and play a role in repairing cartilage and bone tissue in situ.

Constrained Ionizable Cationic Lipids and Lipid Nanoparticles

Resumen de: US2025127728A1

Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.

IONIZABLE LIPIDS WITH BIOACTIVE MOTIFS

Resumen de: US2025127727A1

Provided are ionizable lipids containing a piperazine moiety, as well as lipid nanoparticles that can be formed using the ionizable lipids for use in delivering nucleic acids and other therapeutic agents to specific cell types.

ANISAMIDE-CONTAINING LIPIDS AND COMPOSITIONS AND METHODS OF USE THEREOF

Resumen de: US2025127719A1

The present disclosure relates to ionizable lipidoid compounds comprising an anisamide moiety, and lipid nanoparticles (LNPs) comprising the same. In certain embodiments, the LNP selectively binds to at least one sigma receptor. In certain embodiments, the LNP specifically targets a cell of interest (e.g., a cell expressing a sigma receptor, fibroblast, cancer cell, stromal cell, and epithelial cell, inter alia). In another aspect, the present disclosure provides methods for in vivo delivery of therapeutic agents to treat, prevent, and/or ameliorate diseases and/or disorders, including but not limited to fibrosis and cancer.

2-METHYL-3-PHYTYL-1,4-NAPHTHOQUINONE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES WITH DYSFUNCTION OF VASCULAR ENDOTHELIUM

Resumen de: WO2025084940A1

The invention relate to a compound of the general formula presented in the description of the invention for use in the treatment or prevention of diseases associated with vascular endothelial dysfunction, wherein it is provided in nanocapsules having a diameter of no more than 1 pm, containing a lipophilic core and a hydrophilic shell, wherein the nanocapsules are intended for oral administration.

METHODS AND COMPOSITIONS FOR NUCLEIC CONSTRUCT DELIVERY

Resumen de: WO2025083617A1

The present disclosure includes a composition including a) one or more nucleic acid constructs, wherein the one or more nucleic acid constructs encode: at least one of Replicase 68 (Rep68) and Replicase 78 (Rep78); and at least one protein of viral origin having nucleic acid replication and/or transgene amplification promotion activity, and b) nucleic acid construct comprising a coding region encoding at least one gene of interest (GOI) and at least one inverted terminal repeat (ITR) sequence on each side of the GOI, and methods of making and using the composition.

NANOPARTICLES AND FORMULATIONS THEREOF FOR DELIVERING THERAPEUTIC AGENTS THROUGHOUT THE CENTRAL NERVOUS SYSTEM

Resumen de: WO2025085881A1

Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.

PROTEIN-BASED NANOPARTICLES SUITABLE FOR TUMOUR TARGETING OF ANTI-CANCER DRUGS AND AGENTS

Resumen de: WO2025083423A1

The invention relates to a self-assembling conjugate molecule, the conjugate molecule comprising a hydrophobic polymer covalently bound to human serum albumin (HSA) only at residue Cys34; or a hydrophobic polymer covalently bound to a non-human serum albumin protein only at an equivalent residue to Cys34 of HSA; and associated compositions, uses and methods of treatment.

IONIZABLE LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025082973A1

The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.

ターゲット組織の大きさ又は体積の縮小用組成物、若しくはそれを含むキット

Resumen de: AU2023257167A1

The present invention provides a pharmaceutical composition for treating obesity, the composition including: one or more viruses selected from the group consisting of yellow fever virus, herpes zoster virus, and rubella virus; or a genetic material coding for a protein derived from these viruses. Preferably, the pharmaceutical composition is a vaccine composition. The composition provides a reduction in target tissues, preferably tissues containing adipocytes, or an effect that leads to the death of adipocytes.

凍結乾燥組成物

Nº publicación: JP2025513501A 24/04/2025

Solicitante:

ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー

Resumen de: CN119403545A

The present invention relates to a solid composition obtainable by freeze-drying an aqueous composition comprising rilpivirine or a pharmaceutically acceptable salt thereof and optionally a hyaluronidase. The invention also relates to a reconstituted aqueous composition obtainable by reconstituting a solid composition of the invention, a process for preparing a solid composition of the invention and the use of the reconstituted aqueous composition in the treatment or prevention of HIV infection in a subject.